01—Abstract
Summary
Summary of the 8-K filed March 12, 2024. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (NYSE: COR) announced on March 12, 2024 a planned CEO succession.
Board member selection on March 11, 2024 named Robert P. (Bob) Mauch, the company's current EVP and Chief Operating Officer, to succeed Steven H. Collis as President and CEO effective October 1, 2024, at which point Mauch will also join the Board.
Collis, CEO since July 2011, will become Executive Chairman of the Board for a one-year period. Mauch will receive no additional compensation for Board service, and the company has committed to file an 8-K/A with compensation details once available. For investors, the change is largely a planned, orderly internal succession rather than a strategic reset.
Mauch has been with the company since its 2007 acquisition of Xcenda and has held several senior roles, including Group President and leadership of pharmaceutical distribution and global sourcing, so he is a known quantity. The Board, through Lead Independent Director Mark Durcan, framed the decision as part of a deliberate succession process, and Collis remaining as Executive Chairman provides continuity during the transition. The filing also furnishes a press release reaffirming fiscal 2024 guidance issued on January 31, 2024, which signals management confidence in near-term financial outlook at the time of the announcement.
Information in Item 7.01 is furnished rather than filed, so it is not subject to Section 18 liability. Key items to monitor include the forthcoming compensation disclosure for Mauch and any changes to strategy or guidance at the October 1, 2024 effective date.
02—Key points
Key Highlights
- Robert P. Mauch, EVP and COO, selected to succeed Steven H. Collis as President and CEO effective October 1, 2024
- Mauch, age 57, will also join the Board of Directors on the Effective Date and will receive no additional compensation for Board service
- Collis, CEO since July 2011, becomes Executive Chairman of the Board for a one-year term
- Mauch has been with the company since the 2007 Xcenda acquisition and previously led Group President roles in Pharmaceutical Distribution and Strategic Global Sourcing
- Company reaffirmed fiscal 2024 guidance first outlined on January 31, 2024
- Compensation arrangements for the new CEO have not yet been disclosed and will be filed in an 8-K amendment within four business days after becoming available
- Mauch will be the third CEO in the company's 23-year history, per Collis's statement
03—Questions
Frequently Asked Questions
Why is Cencora changing its CEO?
The filing describes the change as part of the Board's deliberate and thoughtful approach to succession planning. Collis is retiring from the CEO role after more than 13 years, and the Board selected an internal candidate with long experience across the business.
Who is Robert Mauch and what is his background?
Mauch is currently Executive Vice President and Chief Operating Officer, leading all domestic and international business units. He joined in 2007 when Cencora acquired Xcenda, which he founded, and previously served as Group President in Pharmaceutical Distribution & Strategic Global Sourcing and as Group President from 2019 to 2022. He holds a Pharm.D. and a Ph.D. in pharmaceutical science.
What happens to Steven Collis after the transition?
Collis will become Executive Chairman of the Board as of October 1, 2024, serving for a period of one year, to support the new CEO and provide continuity.
Does the announcement change Cencora's financial outlook?
No. The company reaffirmed its fiscal 2024 guidance, originally issued on January 31, 2024, in the same press release announcing the leadership change.
When will investors learn Mauch's compensation package?
The filing states that the company will file an amendment to this Form 8-K disclosing compensation arrangements within four business days after that information becomes available.
04—Continue